The Experts below are selected from a list of 3492 Experts worldwide ranked by ideXlab platform
Tadao Kakizoe - One of the best experts on this subject based on the ideXlab platform.
-
involvement of the anterior Urethra in male patients with transitional cell carcinoma of the bladder undergoing radical cystectomy with simultaneous urethrectomy
Japanese Journal of Clinical Oncology, 1997Co-Authors: Ken Ichi Tobisu, Yae Kanai, Michiie Sakamoto, Hiroyuki Fujimoto, Naoto Doi, Shigeo Horie, Tadao KakizoeAbstract:Histological tumor extension into the Prostate, Urethra and ureters was examined in 52 specimens obtained by cystourethrectomy for transitional cell carcinoma of the bladder with one or more risk factors for Urethral involvement. In four (21.1%) of 19 patients with diffuse carcinoma in situ in the bladder extending to the internal Urethral orifice and prostatic Urethra, the anterior Urethra was affected by transitional cell carcinoma, including one specimen with invasion into the corpus spongiosum. However, none of 33 patients without these findings had synchronous anterior Urethral transitional cell carcinoma involvement. It is recommended that patients with diffuse carcinoma in situ extending into the prostatic Urethra undergo careful preoperative assessment of the anterior Urethra before cystectomy. In other cases, the anterior Urethra can be preserved and used for orthotopic neobladder replacement.
Ken Ichi Tobisu - One of the best experts on this subject based on the ideXlab platform.
-
involvement of the anterior Urethra in male patients with transitional cell carcinoma of the bladder undergoing radical cystectomy with simultaneous urethrectomy
Japanese Journal of Clinical Oncology, 1997Co-Authors: Ken Ichi Tobisu, Yae Kanai, Michiie Sakamoto, Hiroyuki Fujimoto, Naoto Doi, Shigeo Horie, Tadao KakizoeAbstract:Histological tumor extension into the Prostate, Urethra and ureters was examined in 52 specimens obtained by cystourethrectomy for transitional cell carcinoma of the bladder with one or more risk factors for Urethral involvement. In four (21.1%) of 19 patients with diffuse carcinoma in situ in the bladder extending to the internal Urethral orifice and prostatic Urethra, the anterior Urethra was affected by transitional cell carcinoma, including one specimen with invasion into the corpus spongiosum. However, none of 33 patients without these findings had synchronous anterior Urethral transitional cell carcinoma involvement. It is recommended that patients with diffuse carcinoma in situ extending into the prostatic Urethra undergo careful preoperative assessment of the anterior Urethra before cystectomy. In other cases, the anterior Urethra can be preserved and used for orthotopic neobladder replacement.
Michael J Zelefsky - One of the best experts on this subject based on the ideXlab platform.
-
dose to the bladder neck is the most important predictor for acute and late toxicity after low dose rate Prostate brachytherapy implications for establishing new dose constraints for treatment planning
International Journal of Radiation Oncology Biology Physics, 2014Co-Authors: Lara Hathout, Marisa A Kollmeier, Michael R Folkert, Yoshiya Yamada, Gilad N Cohen, Michael J ZelefskyAbstract:Purpose To identify an anatomic structure predictive for acute (AUT) and late (LUT) urinary toxicity in patients with Prostate cancer treated with low-dose-rate brachytherapy (LDR) with or without external beam radiation therapy (EBRT). Methods and Materials From July 2002 to January 2013, 927 patients with Prostate cancer (median age, 66 years) underwent LDR brachytherapy with Iodine 125 (n=753) or Palladium 103 (n=174) as definitive treatment (n=478) and as a boost (n=449) followed by supplemental EBRT (median dose, 50.4 Gy). Structures contoured on the computed tomographic (CT) scan on day 0 after implantation included Prostate, Urethra, bladder, and the bladder neck, defined as 5 mm around the Urethra between the catheter balloon and the prostatic Urethra. AUT and LUT were assessed with the Common Terminology Criteria for Adverse Events, version4. Clinical and dosimetric factors associated with AUT and LUT were analyzed with Cox regression and receiver operating characteristic analysis to calculate area under the receiver operator curve (ROC) (AUC). Results Grade ≥2 AUT and grade ≥2 LUT occurred in 520 patients (56%) and 154 patients (20%), respectively. No grade 4 toxicities were observed. Bladder neck D2cc retained a significant association with AUT (hazard ratio [HR], 1.03; 95% confidence interval [CI], 1.03-1.04; P P =.014) on multivariable analysis. In a comparison of bladder neck with the standard dosimetric variables by use of ROC analysis (Prostate V100 >90%, D90 >100%, V150 >60%, Urethra D20 >130%), bladder neck D2cc >50% was shown to have the strongest prognostic power for AUT (AUC, 0.697; P P Conclusions Bladder neck D2cc >50% was the strongest predictor for grade ≥2 AUT and LUT in patients treated with LDR brachytherapy. These data support inclusion of bladder neck constraints into brachytherapy planning to decrease urinary toxicity.
Yae Kanai - One of the best experts on this subject based on the ideXlab platform.
-
involvement of the anterior Urethra in male patients with transitional cell carcinoma of the bladder undergoing radical cystectomy with simultaneous urethrectomy
Japanese Journal of Clinical Oncology, 1997Co-Authors: Ken Ichi Tobisu, Yae Kanai, Michiie Sakamoto, Hiroyuki Fujimoto, Naoto Doi, Shigeo Horie, Tadao KakizoeAbstract:Histological tumor extension into the Prostate, Urethra and ureters was examined in 52 specimens obtained by cystourethrectomy for transitional cell carcinoma of the bladder with one or more risk factors for Urethral involvement. In four (21.1%) of 19 patients with diffuse carcinoma in situ in the bladder extending to the internal Urethral orifice and prostatic Urethra, the anterior Urethra was affected by transitional cell carcinoma, including one specimen with invasion into the corpus spongiosum. However, none of 33 patients without these findings had synchronous anterior Urethral transitional cell carcinoma involvement. It is recommended that patients with diffuse carcinoma in situ extending into the prostatic Urethra undergo careful preoperative assessment of the anterior Urethra before cystectomy. In other cases, the anterior Urethra can be preserved and used for orthotopic neobladder replacement.
Naoto Doi - One of the best experts on this subject based on the ideXlab platform.
-
involvement of the anterior Urethra in male patients with transitional cell carcinoma of the bladder undergoing radical cystectomy with simultaneous urethrectomy
Japanese Journal of Clinical Oncology, 1997Co-Authors: Ken Ichi Tobisu, Yae Kanai, Michiie Sakamoto, Hiroyuki Fujimoto, Naoto Doi, Shigeo Horie, Tadao KakizoeAbstract:Histological tumor extension into the Prostate, Urethra and ureters was examined in 52 specimens obtained by cystourethrectomy for transitional cell carcinoma of the bladder with one or more risk factors for Urethral involvement. In four (21.1%) of 19 patients with diffuse carcinoma in situ in the bladder extending to the internal Urethral orifice and prostatic Urethra, the anterior Urethra was affected by transitional cell carcinoma, including one specimen with invasion into the corpus spongiosum. However, none of 33 patients without these findings had synchronous anterior Urethral transitional cell carcinoma involvement. It is recommended that patients with diffuse carcinoma in situ extending into the prostatic Urethra undergo careful preoperative assessment of the anterior Urethra before cystectomy. In other cases, the anterior Urethra can be preserved and used for orthotopic neobladder replacement.
